FP-017

FP-017 is a long-acting injectable (LAI) formulation of an undisclosed, highly successful oral antipsychotic medication, currently in preclinical development by Foresee Pharmaceuticals. The drug utilizes Foresee's proprietary Stabilized Injectable Formulation (SIF) technology, a sustained-release delivery system designed to provide long-term therapeutic effects following a single injection. The program aims to improve patient compliance and treatment outcomes in the neurology and psychiatry fields by reducing the frequency of administration and addressing the challenges associated with daily oral dosing. According to company pipeline information, the active ingredient is a successful market product that currently lacks a long-acting injectable equivalent. As of early 2024, the specific active pharmaceutical ingredient and its exact biological targets remain confidential.